NASDAQ:ATOS Atossa Therapeutics (ATOS) Stock Price, News & Analysis $0.84 -0.02 (-2.70%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.84 0.00 (-0.11%) As of 01/31/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Atossa Therapeutics Stock (NASDAQ:ATOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atossa Therapeutics alerts:Sign Up Key Stats Today's Range$0.83▼$0.9250-Day Range$0.83▼$1.3052-Week Range$0.72▼$2.31Volume721,103 shsAverage Volume700,465 shsMarket Capitalization$105.91 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Read More… Atossa Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks23rd Percentile Overall ScoreATOS MarketRank™: Atossa Therapeutics scored higher than 23% of companies evaluated by MarketBeat, and ranked 874th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAtossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtossa Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Atossa Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.22) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Therapeutics is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Therapeutics is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Therapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atossa Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.95% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Atossa Therapeutics has recently increased by 1.98%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtossa Therapeutics does not currently pay a dividend.Dividend GrowthAtossa Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.95% of the outstanding shares of Atossa Therapeutics have been sold short.Short Interest Ratio / Days to CoverAtossa Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Atossa Therapeutics has recently increased by 1.98%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.24 News SentimentAtossa Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Atossa Therapeutics this week, compared to 3 articles on an average week.Search Interest32 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atossa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Atossa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Atossa Therapeutics is held by institutions.Read more about Atossa Therapeutics' insider trading history. Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATOS Stock News HeadlinesAtossa Genetics stock hits 52-week low at $0.75January 30 at 4:27 PM | msn.comAtossa Therapeutics: Strong Strategic Positioning and Patent Resilience Justifies Buy RatingJanuary 30 at 4:27 PM | markets.businessinsider.comYou won’t believe where OpenAI billionaire is investing nowBillionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.February 1, 2025 | Wealthpin Pro (Ad)Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591January 30 at 10:30 AM | finance.yahoo.comAtossa Therapeutics faces patent setback, continues developmentJanuary 30 at 10:30 AM | msn.comAtossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.January 30 at 8:17 AM | globenewswire.comAtossa Therapeutics reports progress in breast cancer treatmentsJanuary 23, 2025 | msn.comAtossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025January 23, 2025 | globenewswire.comSee More Headlines ATOS Stock Analysis - Frequently Asked Questions How have ATOS shares performed this year? Atossa Therapeutics' stock was trading at $0.9441 at the start of the year. Since then, ATOS shares have decreased by 10.8% and is now trading at $0.8419. View the best growth stocks for 2025 here. How were Atossa Therapeutics' earnings last quarter? Atossa Therapeutics, Inc. (NASDAQ:ATOS) announced its earnings results on Monday, August, 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. When did Atossa Therapeutics' stock split? Atossa Therapeutics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Atossa Therapeutics' major shareholders? Top institutional shareholders of Atossa Therapeutics include SG Americas Securities LLC (0.08%). View institutional ownership trends. How do I buy shares of Atossa Therapeutics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atossa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Therapeutics investors own include Zomedica (ZOM), AUO (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK) and The RMR Group (RMR). Company Calendar Last Earnings8/12/2024Today2/01/2025Next Earnings (Estimated)3/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATOS CUSIPN/A CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees8Year Founded2009Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+731.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.74% Return on Assets-33.51% Debt Debt-to-Equity RatioN/A Current Ratio13.30 Quick Ratio13.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book1.15Miscellaneous Outstanding Shares125,800,000Free Float116,240,000Market Cap$105.91 million OptionableOptionable Beta1.26 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ATOS) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.